Natus Medical

History

2022: Investment company ArchiMed bought Natus Medical for $1.2 billion

On April 18, 2022, the manufacturer of neurological equipment Natus Medical announced the conclusion of a final agreement to acquire the investment company ArchiMed Group for a total amount of $1.2 billion.

Under the agreement, Natus shareholders will receive $33.50 in cash for each share of Natus ordinary shares, which represents a 29% premium to the closing price of trading on April 14, 2022.

On April 18, 2022, the manufacturer of neurological equipment Natus Medical announced the conclusion of a final agreement to acquire the investment company ArchiMed Group for a total amount of $1.2 billion.

The sale of Natus Medical to ArchiMed will provide our shareholders with immediate and significant monetary value, as well as an attractive premium, and the board of directors unanimously agreed that this transaction is in the best interests of our shareholders - said Natus Medical Chairman Joshua Levin in a statement filed with the US Securities and Exchange Commission.

The transaction is expected to close in the third quarter of 2022 and is subject to normal closing conditions, approval by Natus shareholders and regulatory approval. The company reports that after the completion of the acquisition, Natus shares will no longer be traded on the public market.

The company's board of directors has already unanimously approved the agreement and recommends that shareholders follow suit. It is expected that after approval by shareholders and fulfillment of other regulatory requirements, the acquisition transaction will be completed in the third quarter of 2022.

Our nearly 1,400 Natus Teammates employees remain committed to advancing treatment standards and improving outcomes and quality of life for patients suffering from brain disorders, nervous pathways and sensory nervous systems, said Thomas J. Sullivan, president and chief executive officer of Natus Medical. A combination of operational, medical, scientific and financial knowledge will ArchiMed help us continue our mission of serving our customers while providing immediate value to shareholders.[1]

Notes